EMYRIA LIMITED - Announcements

Market Cap $12.46M Add to my watchlist

Healthcare

Emyria Limited is an Australia-based early-stage drug development company. The Company is... Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises medication-assisted treatment programs and biopharmaceuticals, specifically methylenedioxy-methylamphetamine (MDMA) analogues and Ultra-Pure cannabidiol (CBD) capsules. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.More

NATURAL MEDICINE LEADERS

The Calmer Co’s MD & CEO, Anthony Noble, highlights the company’s impressive financial performance for FY24.

Announcements

Filter Results

All Price Sensitive Only

EMD	Letter to Shareholders - Adjourned General Meeting		18/03/22	890.21KB	Share
EMD	Addendum to Notice of Meeting and Proxy Form		18/03/22	808.77KB	Share
EMD	Emyria launches second ultra-pure CBD capsule	PRICE SENSITIVE	17/03/22	255.24KB	Share
EMD	EMD-RX5 program advancing Phase 1 clinical trials underway	PRICE SENSITIVE	17/03/22	255.24KB	Share
EMD	Recruitment commenced for EMD-RX5 Phase 1 Study	PRICE SENSITIVE	09/03/22	134.96KB	Share
EMD	Hidden Gems Webinar Presentation		04/03/22	5.28MB	Share
EMD	Ethics approval received for EMD-RX5 Phase 1 Study	PRICE SENSITIVE	03/03/22	135.53KB	Share
EMD	Emyria to present at Hidden Gems Webinar March 4th		02/03/22	138.09KB	Share
EMD	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	990.39KB	Share
EMD	Emyria grows its novel MDMA-analogue library	PRICE SENSITIVE	22/02/22	138.19KB	Share
EMD	General Meeting Adjourned - Letter to Shareholders		22/02/22	232.43KB	Share
EMD	Application for quotation of securities - EMD		14/02/22	25.99KB	Share
EMD	Release of securities from escrow		04/02/22	265.44KB	Share
EMD	Notice under section 708A(5)(e) of the Corporations Act		28/01/22	278.64KB	Share
EMD	Application for quotation of securities - EMD		28/01/22	26.54KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	28/01/22	590.41KB	Share
EMD	Letter to Shareholders - General Meeting		21/01/22	872.16KB	Share
EMD	Notice of General Meeting/Proxy Form		21/01/22	838.71KB	Share
EMD	Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD	PRICE SENSITIVE	20/01/22	269.86KB	Share
EMD	Notification regarding unquoted securities - EMD		31/12/21	29.19KB	Share
EMD	Proposed issue of securities - EMD		30/12/21	25.53KB	Share
EMD	Emyria appoints Sixty Two Capital as corporate advisor		30/12/21	141.25KB	Share
EMD	Notice under section 708A(5)(e) of the Corporations Act		23/12/21	314.42KB	Share
EMD	Application for quotation of securities - EMD		23/12/21	26.51KB	Share
EMD	Change of Registry Address		20/12/21	152.9KB	Share
EMD	Emyria adds wearables to psychedelic-assisted therapy trials	PRICE SENSITIVE	20/12/21	167.02KB	Share
EMD	Trading Halt	PRICE SENSITIVE	16/12/21	696.42KB	Share
EMD	Pause in Trading	PRICE SENSITIVE	16/12/21	115.5KB	Share
EMD	Positive animal data for Emyrias ultra-pure CBD capsule	PRICE SENSITIVE	15/12/21	236.96KB	Share
EMD	Positive initial MDMA-analogue screening results	PRICE SENSITIVE	08/12/21	145.86KB	Share
EMD	Change of Director's Interest Notice KS		07/12/21	239.22KB	Share
EMD	Application for quotation of securities - EMD		06/12/21	29.04KB	Share
EMD	Notice under section 708A(5)(e) of the Corporations Act		01/12/21	314.12KB	Share
EMD	Application for quotation of securities - EMD		01/12/21	26.51KB	Share
EMD	Application for quotation of securities - EMD		01/12/21	26.76KB	Share
EMD	Initial Director's Interest Notice KS		30/11/21	133.33KB	Share
EMD	Emyria Appoints Global Pharma Expert Dr Karen Smith to Board		29/11/21	163.93KB	Share
EMD	Emyria Anoints Global Pharma Expert Dr Karen Smith to Board		29/11/21	163.93KB	Share
EMD	Change in substantial holding SW		26/11/21	110.15KB	Share
EMD	Change in substantial holding MW		26/11/21	134KB	Share
EMD	Change in substantial holding MT		26/11/21	102.7KB	Share
EMD	Change in substantial holding CD		26/11/21	104.77KB	Share
EMD	Becoming a substantial holder TAT		25/11/21	97.09KB	Share
EMD	Notification regarding unquoted securities - EMD		24/11/21	29.1KB	Share
EMD	Application for quotation of securities - EMD		24/11/21	26.5KB	Share
EMD	Notice under section 708A(5)(e) of the Corporations Act		24/11/21	314.84KB	Share
EMD	Emyria receives $1,162,000 R&D Tax Incentive Refund	PRICE SENSITIVE	24/11/21	141.05KB	Share
EMD	Application for quotation of securities - EMD		22/11/21	26.69KB	Share
EMD	Proposed issue of securities - EMD		22/11/21	28.34KB	Share
EMD	Emyria Welcomes Tattarang as Strategic Investor	PRICE SENSITIVE	22/11/21	230.86KB	Share
EMD	Trading Halt	PRICE SENSITIVE	19/11/21	702.94KB	Share
EMD	Results of Meeting		03/11/21	146.11KB	Share
EMD	Notification regarding unquoted securities - EMD		01/11/21	28.32KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	26/10/21	327.47KB	Share
EMD	MDMA Analogue Development Milestone	PRICE SENSITIVE	19/10/21	139.18KB	Share
EMD	Notification of cessation of securities - EMD		18/10/21	23.24KB	Share
EMD	Notification of cessation of securities - EMD		18/10/21	23.34KB	Share
EMD	Notification of cessation of securities - EMD		18/10/21	23.34KB	Share
EMD	Notification regarding unquoted securities - EMD		08/10/21	28.4KB	Share
EMD	Emyria selected to join Palantirs Foundry Builders Program	PRICE SENSITIVE	07/10/21	385.08KB	Share
EMD	EMD Welcomes TGA-Commissioned Report on MDMA and Psilocybin		01/10/21	145.86KB	Share
EMD	Annual Report to shareholders		01/10/21	3.21MB	Share
EMD	Appendix 4G		30/09/21	282.3KB	Share
EMD	Letter to Shareholders - Annual General Meeting		30/09/21	800.56KB	Share
EMD	Notice of Annual General Meeting/Proxy Form		30/09/21	786.59KB	Share
EMD	Lifesciences Webinar Presintation		28/09/21	4.14MB	Share
EMD	Novel MDMA Analogue Screening Program Advanced	PRICE SENSITIVE	22/09/21	145.51KB	Share
EMD	Notification regarding unquoted securities - EMD		22/09/21	27.47KB	Share
EMD	Emyria Expands Psychiatry Advisory for Psychedelics and MDMA	PRICE SENSITIVE	16/09/21	269.06KB	Share
EMD	MDMA-analogues Show Promise for Parkinson's Disease	PRICE SENSITIVE	01/09/21	429.22KB	Share
EMD	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	31/08/21	1.31MB	Share
EMD	Annual General Meeting		31/08/21	135.89KB	Share
EMD	Emyria Engages Calvert Labs for Preclinical CBD studies	PRICE SENSITIVE	27/08/21	144.91KB	Share
EMD	Emyria Drug Development Overview and Webinar		23/08/21	5.91MB	Share
EMD	Emyria Appoints Expert Neuropharmacologist for MDMA Program	PRICE SENSITIVE	20/08/21	144.04KB	Share
EMD	Emyria Executes Pure CBD Agreement with AltaSciences	PRICE SENSITIVE	13/08/21	150.95KB	Share
EMD	CAN: Cann and Emyria mutually end collaboration	PRICE SENSITIVE	13/08/21	198.02KB	Share
EMD	Emyria and Cann Mutually End Collaboration	PRICE SENSITIVE	13/08/21	146.93KB	Share
EMD	Emyria to Develop Novel Psychedelics Pipeline with UWA	PRICE SENSITIVE	05/08/21	161.32KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	28/07/21	479.05KB	Share
EMD	Principal Investigator Appointed to lead Emyria MDMA trial		29/06/21	174.62KB	Share
EMD	Results of Meeting		18/06/21	148.22KB	Share
EMD	Webinar Presentation		18/06/21	5.34MB	Share
EMD	Investor Webinar Presentation Today		18/06/21	131.68KB	Share
EMD	Emyria Advances EMD-004 Program Towards Registration	PRICE SENSITIVE	15/06/21	147.96KB	Share
EMD	Emyria Investor Webinar		07/06/21	134.61KB	Share
EMD	Emyria Data Validated, Care Model Reduces Opioids	PRICE SENSITIVE	07/06/21	10.36MB	Share
EMD	Details of Company Address		19/05/21	76.19KB	Share
EMD	Notice of General Meeting/Proxy Form		17/05/21	775.72KB	Share
EMD	Emyria Obtains TGA Approval for Medical Grade Monitoring App	PRICE SENSITIVE	12/05/21	439.83KB	Share
EMD	Trading Halt	PRICE SENSITIVE	11/05/21	505.68KB	Share
EMD	Emyria and MMA launch MDMA-assisted therapy program for PTSD	PRICE SENSITIVE	05/05/21	187.44KB	Share
EMD	Appendix 2A and Notice Under Section 708A		28/04/21	360.7KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	28/04/21	861KB	Share
EMD	Proposed issue of Securities - EMD		21/04/21	26.42KB	Share
EMD	Proposed issue of Securities - EMD		21/04/21	29.25KB	Share
EMD	$5m Placement for Drug Registration and Treatment Pipeline	PRICE SENSITIVE	21/04/21	146.91KB	Share
EMD	Trading Halt	PRICE SENSITIVE	19/04/21	369.93KB	Share
EMD	Emyria Drug Registration Model - EMD-003 snapshot		07/04/21	4.8MB	Share
EMD	CAN: Cann and Emyria investor webinar		30/03/21	174.45KB	Share

EMD Letter to Shareholders - Adjourned General Meeting
18/03/22		890.21KB	Share
EMD Addendum to Notice of Meeting and Proxy Form
18/03/22		808.77KB	Share
EMD Emyria launches second ultra-pure CBD capsule
17/03/22	PRICE SENSITIVE	255.24KB	Share
EMD EMD-RX5 program advancing Phase 1 clinical trials underway
17/03/22	PRICE SENSITIVE	255.24KB	Share
EMD Recruitment commenced for EMD-RX5 Phase 1 Study
09/03/22	PRICE SENSITIVE	134.96KB	Share
EMD Hidden Gems Webinar Presentation
04/03/22		5.28MB	Share
EMD Ethics approval received for EMD-RX5 Phase 1 Study
03/03/22	PRICE SENSITIVE	135.53KB	Share
EMD Emyria to present at Hidden Gems Webinar March 4th
02/03/22		138.09KB	Share
EMD Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	990.39KB	Share
EMD Emyria grows its novel MDMA-analogue library
22/02/22	PRICE SENSITIVE	138.19KB	Share
EMD General Meeting Adjourned - Letter to Shareholders
22/02/22		232.43KB	Share
EMD Application for quotation of securities - EMD
14/02/22		25.99KB	Share
EMD Release of securities from escrow
04/02/22		265.44KB	Share
EMD Notice under section 708A(5)(e) of the Corporations Act
28/01/22		278.64KB	Share
EMD Application for quotation of securities - EMD
28/01/22		26.54KB	Share
EMD Appendix 4C - Quarterly
28/01/22	PRICE SENSITIVE	590.41KB	Share
EMD Letter to Shareholders - General Meeting
21/01/22		872.16KB	Share
EMD Notice of General Meeting/Proxy Form
21/01/22		838.71KB	Share
EMD Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD
20/01/22	PRICE SENSITIVE	269.86KB	Share
EMD Notification regarding unquoted securities - EMD
31/12/21		29.19KB	Share
EMD Proposed issue of securities - EMD
30/12/21		25.53KB	Share
EMD Emyria appoints Sixty Two Capital as corporate advisor
30/12/21		141.25KB	Share
EMD Notice under section 708A(5)(e) of the Corporations Act
23/12/21		314.42KB	Share
EMD Application for quotation of securities - EMD
23/12/21		26.51KB	Share
EMD Change of Registry Address
20/12/21		152.9KB	Share
EMD Emyria adds wearables to psychedelic-assisted therapy trials
20/12/21	PRICE SENSITIVE	167.02KB	Share
EMD Trading Halt
16/12/21	PRICE SENSITIVE	696.42KB	Share
EMD Pause in Trading
16/12/21	PRICE SENSITIVE	115.5KB	Share
EMD Positive animal data for Emyrias ultra-pure CBD capsule
15/12/21	PRICE SENSITIVE	236.96KB	Share
EMD Positive initial MDMA-analogue screening results
08/12/21	PRICE SENSITIVE	145.86KB	Share
EMD Change of Director's Interest Notice KS
07/12/21		239.22KB	Share
EMD Application for quotation of securities - EMD
06/12/21		29.04KB	Share
EMD Notice under section 708A(5)(e) of the Corporations Act
01/12/21		314.12KB	Share
EMD Application for quotation of securities - EMD
01/12/21		26.51KB	Share
EMD Application for quotation of securities - EMD
01/12/21		26.76KB	Share
EMD Initial Director's Interest Notice KS
30/11/21		133.33KB	Share
EMD Emyria Appoints Global Pharma Expert Dr Karen Smith to Board
29/11/21		163.93KB	Share
EMD Emyria Anoints Global Pharma Expert Dr Karen Smith to Board
29/11/21		163.93KB	Share
EMD Change in substantial holding SW
26/11/21		110.15KB	Share
EMD Change in substantial holding MW
26/11/21		134KB	Share
EMD Change in substantial holding MT
26/11/21		102.7KB	Share
EMD Change in substantial holding CD
26/11/21		104.77KB	Share
EMD Becoming a substantial holder TAT
25/11/21		97.09KB	Share
EMD Notification regarding unquoted securities - EMD
24/11/21		29.1KB	Share
EMD Application for quotation of securities - EMD
24/11/21		26.5KB	Share
EMD Notice under section 708A(5)(e) of the Corporations Act
24/11/21		314.84KB	Share
EMD Emyria receives $1,162,000 R&D Tax Incentive Refund
24/11/21	PRICE SENSITIVE	141.05KB	Share
EMD Application for quotation of securities - EMD
22/11/21		26.69KB	Share
EMD Proposed issue of securities - EMD
22/11/21		28.34KB	Share
EMD Emyria Welcomes Tattarang as Strategic Investor
22/11/21	PRICE SENSITIVE	230.86KB	Share
EMD Trading Halt
19/11/21	PRICE SENSITIVE	702.94KB	Share
EMD Results of Meeting
03/11/21		146.11KB	Share
EMD Notification regarding unquoted securities - EMD
01/11/21		28.32KB	Share
EMD Appendix 4C - Quarterly
26/10/21	PRICE SENSITIVE	327.47KB	Share
EMD MDMA Analogue Development Milestone
19/10/21	PRICE SENSITIVE	139.18KB	Share
EMD Notification of cessation of securities - EMD
18/10/21		23.24KB	Share
EMD Notification of cessation of securities - EMD
18/10/21		23.34KB	Share
EMD Notification of cessation of securities - EMD
18/10/21		23.34KB	Share
EMD Notification regarding unquoted securities - EMD
08/10/21		28.4KB	Share
EMD Emyria selected to join Palantirs Foundry Builders Program
07/10/21	PRICE SENSITIVE	385.08KB	Share
EMD EMD Welcomes TGA-Commissioned Report on MDMA and Psilocybin
01/10/21		145.86KB	Share
EMD Annual Report to shareholders
01/10/21		3.21MB	Share
EMD Appendix 4G
30/09/21		282.3KB	Share
EMD Letter to Shareholders - Annual General Meeting
30/09/21		800.56KB	Share
EMD Notice of Annual General Meeting/Proxy Form
30/09/21		786.59KB	Share
EMD Lifesciences Webinar Presintation
28/09/21		4.14MB	Share
EMD Novel MDMA Analogue Screening Program Advanced
22/09/21	PRICE SENSITIVE	145.51KB	Share
EMD Notification regarding unquoted securities - EMD
22/09/21		27.47KB	Share
EMD Emyria Expands Psychiatry Advisory for Psychedelics and MDMA
16/09/21	PRICE SENSITIVE	269.06KB	Share
EMD MDMA-analogues Show Promise for Parkinson's Disease
01/09/21	PRICE SENSITIVE	429.22KB	Share
EMD Appendix 4E and Full Year Statutory Accounts
31/08/21	PRICE SENSITIVE	1.31MB	Share
EMD Annual General Meeting
31/08/21		135.89KB	Share
EMD Emyria Engages Calvert Labs for Preclinical CBD studies
27/08/21	PRICE SENSITIVE	144.91KB	Share
EMD Emyria Drug Development Overview and Webinar
23/08/21		5.91MB	Share
EMD Emyria Appoints Expert Neuropharmacologist for MDMA Program
20/08/21	PRICE SENSITIVE	144.04KB	Share
EMD Emyria Executes Pure CBD Agreement with AltaSciences
13/08/21	PRICE SENSITIVE	150.95KB	Share
EMD CAN: Cann and Emyria mutually end collaboration
13/08/21	PRICE SENSITIVE	198.02KB	Share
EMD Emyria and Cann Mutually End Collaboration
13/08/21	PRICE SENSITIVE	146.93KB	Share
EMD Emyria to Develop Novel Psychedelics Pipeline with UWA
05/08/21	PRICE SENSITIVE	161.32KB	Share
EMD Appendix 4C - Quarterly
28/07/21	PRICE SENSITIVE	479.05KB	Share
EMD Principal Investigator Appointed to lead Emyria MDMA trial
29/06/21		174.62KB	Share
EMD Results of Meeting
18/06/21		148.22KB	Share
EMD Webinar Presentation
18/06/21		5.34MB	Share
EMD Investor Webinar Presentation Today
18/06/21		131.68KB	Share
EMD Emyria Advances EMD-004 Program Towards Registration
15/06/21	PRICE SENSITIVE	147.96KB	Share
EMD Emyria Investor Webinar
07/06/21		134.61KB	Share
EMD Emyria Data Validated, Care Model Reduces Opioids
07/06/21	PRICE SENSITIVE	10.36MB	Share
EMD Details of Company Address
19/05/21		76.19KB	Share
EMD Notice of General Meeting/Proxy Form
17/05/21		775.72KB	Share
EMD Emyria Obtains TGA Approval for Medical Grade Monitoring App
12/05/21	PRICE SENSITIVE	439.83KB	Share
EMD Trading Halt
11/05/21	PRICE SENSITIVE	505.68KB	Share
EMD Emyria and MMA launch MDMA-assisted therapy program for PTSD
05/05/21	PRICE SENSITIVE	187.44KB	Share
EMD Appendix 2A and Notice Under Section 708A
28/04/21		360.7KB	Share
EMD Appendix 4C - Quarterly
28/04/21	PRICE SENSITIVE	861KB	Share
EMD Proposed issue of Securities - EMD
21/04/21		26.42KB	Share
EMD Proposed issue of Securities - EMD
21/04/21		29.25KB	Share
EMD $5m Placement for Drug Registration and Treatment Pipeline
21/04/21	PRICE SENSITIVE	146.91KB	Share
EMD Trading Halt
19/04/21	PRICE SENSITIVE	369.93KB	Share
EMD Emyria Drug Registration Model - EMD-003 snapshot
07/04/21		4.8MB	Share
EMD CAN: Cann and Emyria investor webinar
30/03/21		174.45KB	Share

REFRESH

First 2 3 4

(20min delay)
Last 3.0¢		Change -0.003(9.09%)		Mkt cap ! $12.46M

Open	High	Low	Value	Volume
3.1¢	3.1¢	3.0¢	$8.437K	272.3K

Buyers (Bids)

No.	Vol.	Price($)
8	448106	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
3.3¢	65063	2

View Market Depth

No.	Vol.	Price($)
8	448106	0.030
4	110414	0.029
3	41500	0.028
1	111111	0.027
1	336336	0.026

Price($)	Vol.	No.
0.033	65063	2
0.034	193645	1
0.036	72967	1
0.037	31300	1
0.038	26315	1

Last trade - 11.44am 07/11/2024 (20 minute delay)


Last 3.1¢		Change -0.003 ( 0.00 %)
Open	High	Low	Volume
3.1¢	3.1¢	3.1¢	30891
Last updated 11.22am 07/11/2024 ?

EMD (ASX) Chart

EMYRIA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories